Biosimilar launches achieve a 53% market share and a 53% reduction in average drug costs after 5 years of biosimilar ...
A study from Spain found a subcutaneous tocilizumab biosimilar to be cost-effective when treating patients with rheumatoid ...
Achieving global regulatory harmonization for biosimilar vaccines and immunotherapies is essential to improving market access ...
The Top 5 Biosimilar Articles for the Week of December 2 ...
The Top 5 Biosimilar Articles for the Week of December 2 ...
The Top 5 Biosimilar Articles for the Week of December 2 ...
The US oncology biosimilar market has rapidly evolved since its launch in 2017, driven by steep price discounts, payer ...
The Top 5 Biosimilar Articles for the Week of December 2 ...
Celltrion’s denosumab biosimilar demonstrated equivalent efficacy, safety, and immunogenicity compared with the originator in a phase 3 trial involving postmenopausal women with osteoporosis, paving ...
Korean drugmakers hold over 50% market share in the 6 best-selling biosimilar markets, 2 companies sign exclusive licensing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback